299

PRESENTED BY MEDICAL ONLINE

Collod-Hepatogram with Phytate-Tc-99m

N. Uehara, F. Tsunoda, K. Mizutani, Y. Eguchi,
M. Kodama, Y. Takekoto, and K. Masuda
University of Medical Sciences, Shiga

Phytate-Tc-99m is one of the most popular radiopharmaceuticals for liver scintigraphy, is thought to be arrested in K.E.S., especially in the liver by Kupffer cells. Liver uptake index (KI) of phytate demonstrates the dependence, so it reflects not only liver bloodflow but also Kupffer cell function. KI in various hepatobiliary diseases are 0.183 ? 0.026 in liver cirrhosis, 0.231 ± 0.033 in hepatoma without cirrhosis, 0.256 ± 0.040 in biliary neoplasms and 0.249 ± 0.015 in miscellaneous benign biliary diseases. KI showed significant correlation with ICG-KO_5, ICG-Rmax, (p < 0.05), CH_2, ZTT (p < 0.01) and Fibrinogen (p < 0.005), respectively. The fate of phytate phagocytosed by Kupffer cells is still unclear. In our three cases, RI-activity was detected in tube-drained bile early in the post-injection period and reached its maximum value as early as in one hour. After operation (most of them are partial hepatectomy), colloidal uptake of spleen (S/S+L) increased and KI decreased suggesting that effective liver bloodflow decreases and compensation or congestion of spleen results, though we could not differentiate them from each other.

300

COMPARISON OF COLLOID LIVER SCAN, COMPUTED TOMOGRAPHY AND GRAY-SCALE ULTRASONOGRAPHY IN THE EVALUATION OF THE DIFFUSE LIVER DISEASE PROVEN BY THE PERITONEOSCOPIC BIOPSY.

S. Taniguchi, S. Tanaka, T. Okamura, M. Tsumura,
A. Sazaki, T. Takekoto, H. Ochi, Y. Nomura,
A. Shimonishi, M. Omura, H. Ikeda, K. Hamada,
S. Shiomi, N. Kurioka and T. Kuroki.Osaka City University School of Medicine, Osaka.

Seventy cases of the diffuse liver diseases (cirrhosis, 26; pre-cirrhosis, 5; active chronic hepatitis, 12; inactive chronic hepatitis, 5; acute hepatitis, 5; fulminant hepatitis, 6; biliary stasis, 5; fatty metamorphosis, 4; others, 2) proven by the peritoneoscopic biopsy were studied with three modalities such as colloid liver scan, X-CT and gray-scale ultrasonography.

On the colloid liver scan, the size of the liver and spleen, the liver and spleen size ratio, the RI distribution of the liver, spleen and bone marrow were evaluated. On X-CT, the size, surface and the CT number of the liver and spleen, the liver and spleen size ratio, the diameter of the portal vein were evaluated. On gray-scale ultrasonography, liver deformity, edge, surface, intrahepatic echo, splenomegaly were graded.

We reported the role, characteristic and weak point of the three modalities for diagnosis of the diffuse liver diseases.

301

CLINICAL EVALUATION OF PROGRESS OF DIFFUSE HEPATIC DISEASES BY LIVER SCINTIGRAPHY USING TC-99M-SULFUR COLLOID - CORRELATION BETWEEN ITS INTER-ORGAN UPTAKE RATIO AND BIOLOGY FINDINGS.

T. Kimura, A. Suzuki, Y. Sakata, M. Okawa and Y. Komatsu
First Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki

Correlation between scintigraphic inter-organ uptake ratio and biopsy findings was studied in 34 cases with diffuse hepatic diseases, including 8 cases of non-specific reactive hepatitis (NSRH), 8 cases of chronic inactive hepatitis (CIH), 12 cases of chronic active hepatitis (CAH), 2 cases of liver cirrhosis (LC). Using a computer-interfaced scintillation camera, regions of interest corresponding to liver (L), spleen (S), bone marrow (BM) and background (BG) were selected, and the ratios were computed among each other. Biopsy findings of piecemeal necrosis (PN), necrosis (N), portal fibrosis (PF) and Kupffer cell mobilization (K) were divided into five grades respectively. In CAH, significant correlation was showed between PF and L/S, N and S/BG, N and L/S (Spearman rank correlation coefficient).

Additionally, BM/SG and L/SM showed significant difference between LC and non-LC. With ranking the four disease category from 1 to 4 in order of NSRH, CIH, CAH and LC, significant correlation was present between this ranking and L/SM. Conclusively, it was suggested that liver scintigraphy is beneficial to evaluating progress of diffuse hepatic diseases.